Articles

Reported highlights from sessions held during the 2009 XXVII ESCRS Congress in Barcelona, Spain.

Patients with neovascular AMD maintain visual acuity.

2009 heralded more interesting developments for ophthalmology. OTEurope asked some of Europe's leading key opinion leaders for their thoughts on the news and developments that generated most excitement or had most significance in the Cataract & Refractive sector

Sponsored Feature. Xalatan® is to become available across Europe in a newly designed bottle. So what does that mean and what lies behind that decision?

What should you be concentrating on with severe corneal burns?

A procedure that uses microwaves to alter corneal refraction may be alternative to LASIK in myopia patients

Optic design modification enhances vision performance without degrading contrast sensitivity

European School for Advanced Studies in Ophthalmology

Treating corneal neovascularization and the need for new and better treatments.

Greater, more consistent reductions seen throughout the day compared with brimonidine.

Nowadays ophthalmic surgeons have several treatment options for astigmatism. In Dr Detlef Holland's refractive department toric IOL and LASIK are the main options used.

Simultaneous IOPg, IOPcc measurements may provide significant data about patient groups.

Tips and techniquess for cataract and refractive success: The dry eye connection.

San Francisco?Anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration represent the most significant advancement in ophthalmology over the past decade, according to 52% of respondents to an online survey of members of the American Academy of Ophthalmology conducted in December.

Palomid 529 (P529) is to enter its Phase I trial in patients with AMD. A Phase I Open-Label Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Single Intravitreal and Subconjunctival Doses of Palomid 529 in Patients with Advanced Neovascular Age-Related Macular Degeneration will according to Paloma Pharmaceuticals, be a dose-ranging study for safety but will also have an objective measure for efficacy.

Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.9

Eye advance online publication 12 February 2010; doi: 10.1038/eye.2010.3

VEGF Trap-Eye, the fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related Placental Growth Factor (PIGF), has shown positive results in a Phase 2 study in patients with diabetic macular oedema (DME.

Researchers in the journal, Archives of Ophthalmology have indicated that results from a 4-year study of more than 21,000 Americans point to an association between glaucoma medications and a lower death rate.

LUVENIQ (LX211; oral voclosporin) has been filed for approval by the European Medicines Agency (EMA) and the US's Food and Drug Administration by Lux Biosciences. The drug is aimed at treatment of non-infectious uveitis for the intermediate or posterior segments of the eye.

Coherent is unique amongst laser manufacturers in the breadth of our excimer laser product portfolio and the depth of our experience in building products for both Laser-Assisted In Situ Keratomileusis (LASIK) and other refractive techniques.

A paper entitled A Placebo-Controlled Trial of Microplasmin Intravitreous Injection to Facilitate Posterior Vitreous Detachment Before Vitrectomy has been published online ahead of print in Ophthalmology.

Pfizer's CEO, Jeffrey Kindler has received the 2010 Catalyst Award, the Glaucoma Research Foundation's highest honour, acknowledging his role in sustaining innovative research and education.

An international course on ophthalmic and oculoplastic reconstruction and trauma surgery will be taking place in Vienna from April 15-17 at the Vienna General Hospital/Neurosurgical Laboratory.

iPhot, the collaborative project for continuing the development of Imagine Eyes' rtx1 Adaptive Optics Retinal Camera has received a 940K€ (approximately $US1.35M) grant from France's National Research Agency (ANR) TecSan programme.

The Glaucoma Research Foundation (GRF) awarded the 2010 Shaffer Prize for Innovative Glaucoma Research to Kate Keller, PhD. Dr Keller is Research Assistant Professor, Department of Ophthalmology at Casey Eye Institute in Portland, Oregon.

More than 150 participants from 27 countries attended this year's SCHWIND User Meeting in Muscat, Oman.

Retinitis pigmentosa and AMD may be the beneficiaries of a new tool for gene therapy that significantly increases gene delivery to cells in the retina.

Australia's Centre for Eye Research has discovered a hepatocyte growth factor (HGF) gene, which it hopes will provide important insights into biological mechanisms involved in ocular development.

Hans Werquin will become CEO of Hoya Vision Care Europe from the beginning of April 2010. He will report to Gerald Bottero, who has been leading the European branch for the past five years. Bottero remains CEO of Hoya Vision Care globally.